Hepatitis C virus infection in Taiwan: Past, present, and future

Journal of the Formosan Medical Association

Volumn 115, Issue 2, 2016, Pages 65-66

  Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BOCEPREVIR; ELBASVIR PLUS GRAZOPREVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT;

HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TREATMENT RESPONSE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; PUBLIC HEALTH;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; PUBLIC HEALTH; RIBAVIRIN; TAIWAN;

EID: 84960264071     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.06.012     Document Type: Short Survey

References (8)

1. Liu C.H., Kao J.H. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014, 9:2051-2067.
2. Chen D.S. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011, 54:381-392.
3. Liu C.H., Liu C.J., Lin C.L., Liang C.C., Hsu S.J., Yang S.S., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
4. Hsu C.S., Chao Y.C., Lin H.H., Chen D.S., Kao J.H. Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep 2015, 5:9954.
5. Hsu C.S., Hsu S.J., Chen H.C., Tseng T.C., Liu C.H., Niu W.F., et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A 2011, 108:3719-3724.
6. Su T.H., Liu C.H., Liu C.J., Chen C.L., Ting T.T., Tseng T.C., et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A 2013, 110:7844-7849.
7. Lin J.A., Chen Y.C., Cheng S.N., Chen P.J., Chu H.C., Hsieh T.Y., et al. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan. J Formos Med Assoc 2014, 113:727-733.
8. Hayes C.N., Chayama K. Emerging treatments for chronic hepatitis C. J Formos Med Assoc 2015, 114:204-215.